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High nephritogenicity of monoclonal antibodies belonging to
IgG2a and IgG2b subclasses in rat anti-GBM nephritis.
Background. To examine a subclass-effect relationship
and a dose-effect relationship of autoantibodies in the rat
antiglomerular basement membrane (GBM) antibody-induced
glomerulonephritis (anti-GBM nephritis) model, we injected
homologous monoclonal antibodies against the NC1 domains
of rat type IV collagen into inbred Wistar-Kyoto (WKY) rats.
Methods. Eight different autoantibodies from each of the
IgG1, IgG2a, and IgG2b subclasses were established and ad-
ministered to groups of four WKY rats at a dose of 300 lg/rat.
To examine the dose-effect relationship, we administered 0 to
300 lg/rat of autoantibodies from each subclass to rats.
Results. All IgG1 antibodies induced mild nephritis, whereas
the IgG2a and IgG2b antibodies induced moderate to severe
nephritis. Some IgG2a and IgG2b antibodies induced pul-
monary hemorrhage as well. These antibodies were reactive
with a3(IV)NC1, a4(IV)NC1, or a5(IV)NC1. The minimum
dose of antibody required to induce nephritis was 30 lg/rat for
IgG1, 3 lg/rat for IgG2a, and 1 lg/rat for IgG2b. At doses of
30 lg/rat or less, antibody deposition was generally restricted to
the GBM. At doses of 100 lg/rat or greater, antibody deposition
extended to both the GBM and tubular basement membrane
(TBM). Pulmonary hemorrhage was observed only when a large
amount of pulmonary hemorrhagic antibody was administered.
Conclusion. The severity of nephritis was dependent on both
subclass and dose of autoantibodies. It becomes clear that
pulmonary hemorrhage in anti-GBM nephritis is induced by
autoantibodies.
Antiglomerular basement membrane (GMB) anti-
body-induced glomerulonephritis (anti-GBM nephritis)
is induced by autoantibody against the renal GBM.
Approximately one half of cases are accompanied by
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pulmonary hemorrhage, a pathologic condition known
as Goodpasture syndrome [1, 2]. Antibodies against
the NC1 domains of type IV collagen alpha chains
[a(IV)NC1] are found in the serum of patients with the
disease; and, in particular, high titers of antibody against
a3(IV)NC1 are found [3–7]. There are six genetically dif-
ferent isoforms of type IV collagen alpha chains, num-
bered from a1(IV) to a6(IV). The amino acid sequences
of these chains have already been identified in humans
[8]. Three of these isoforms assemble to form a single he-
lical collagen molecule [9–12]. Combinations of a1/a1/a2,
a3/a4/a5, and a5/a5/a6 have been observed. The GBM
contains collagen primarily composed of a3/a4/a5 chains,
but a1/a1/a2 collagen has also been observed on the en-
dothelial cell side of the GBM.
There are two types of rat models of experimental anti-
GBM nephritis. The first involves actively induced anti-
GBM nephritis elicited by the injection of an emulsion
containing nephritogenic antigen and Freund’s complete
adjuvant. The antigen is derived from solubilized GBM
[13], or a purified fraction containing a(IV)NC1 domains
[14]. Synthetic a3(IV)NC1 or a4(IV)NC1 peptide se-
quences[15] or recombinant a3(IV)NC1 or a4(IV)NC1
proteins [16–18] have also be used. Studies on actively in-
duced anti-GBM nephritis have revealed the target anti-
gen of nephritis to be a3(IV)NC1 and a4(IV)NC1. These
nephritogenic antigens can be used for the diagnosis of
human anti-GBM nephritis [6, 7, 19], indicating that the
actively induced model in rats is very similar to human
anti-GBM nephritis.
The second model, in which antibodies against GBM
or a(IV)NC1 domains are administered to rats, results
in passively induced anti-GBM nephritis. Nephritogenic
polyclonal antibody fraction can be obtained from the
urine of nephritic rats with actively induced anti-GBM
nephritis [20], and nephritogenic monoclonal antibod-
ies can be obtained from the culture supernatant of
hybridoma cells [21]. The ability of antibodies to in-
duce nephritis clearly indicates that anti-GBM nephritis
177
178 Kohda et al: Nephritogenic monoclonal antibodies
is mediated by humoral immuinity. This does not
completely exclude the involvement of cellular immu-
nity because there are reports by Wu et al [18, 22]. They
reported that on a transfer of in vitro-activated T cell
lines to pertussis toxin-primed, naive syngeneic Wistar-
Kyoto (WKY) rats, the recipients developed severe pro-
teinuria/albuminuria but the rats have no deposition of
IgG on the GBM [22].
However, only three clones of nephritogenic mono-
clonal antibodies have been characterized [15, 21], and
this number is too small to know the nature and function
of nephritogenic autoantibodies. In 1995 we reported a
new monoclonal-antibody-producing method called the
rat lymph node method [23]. Enlarged medial iliac lymph
nodes from antigen-injected rats are used for cell fusion
with mouse myeloma cells, and an approximately tenfold
greater number of positive enzyme-linked immunosor-
bent assay (ELISA) wells containing antibodies can be
obtained by this technique than by other ones. By us-
ing this method, we were able to obtain more than 100
monoclonal antibodies against type IV collagen, repre-
senting three different IgG subclasses (i.e., IgG1, 2a, and
2b). Using some of these established antibodies, we exam-
ined the nephritogenicity of different antibody subclasses
and the dose-effect relationships of these nephritogenic
antibodies.
METHODS
Animals
Female WKY/NCrj inbred rats were purchased from
Charles River Japan, Inc. (Yokohama, Japan). The rats
were housed in polycarbonate plastic cages containing
wood shavings as bedding. They were given free access
to drinking water and food. The animal experiments in
the present study were conducted according to the Guide-
lines for Laboratory Animal Experiments of the Shigei
Medical Research Institute and Laboratory Animal Re-
search Center, Faculty of Medicine, Tottori University.
Production of monoclonal antibodies
The monoclonal antibodies used in the present study
were produced by the rat lymph node method [23]. The
immunizing antigen was a rat nephritogenic antigen frac-
tion (NAF) purified by a method of purification similar to
that used for the human nephritogenic antigen fraction
[21, 24]. Medial iliac lymph nodes of WKY rats immu-
nized with the rat antigen were obtained 3 weeks after
the injection and fused with mouse SP2 myeloma cells.
Hybridomas producing antibodies that were able to stain
rat basement membranes of frozen kidney sections with
+++ intensity were selected and cloned.
GIT culture medium (Wako Pure Chemical Industries,
Osaka, Japan) containing 10% fetal bovine serum (FBS)
was used for hybridoma cultures. We prepared highly con-
centrated supernatants from the antibody-positive cul-
tures by using a rotation culture system (Mini Perm with
a classic/12.5 kD production module) (Vivascience, Han-
nover, Germany). The hybridomas were cultured for 2
weeks. The culture medium of the nutrient module was
changed three times, on days 7, 9, and 11 of the culture
period.
We determined antibody concentrations with MEP-
Hyper Cel gel (Ciphergen Biosystems, Inc., Cergy Saint-
Christophe, France). Rat antibodies bind strongly to this
affinity gel in a column at neutral pH, but they are eluted
from the gel at pH 4.0 with little denaturation. We mea-
sured the absorbance of the eluted antibodies at 280 nm.
An extinction coefficient of 1.46 was used for the anti-
bodies. Concentrations of the antibodies obtained from
rotation cultures ranged from 1 to 3 mg/mL.
Characterization of the monoclonal antibodies
ELISA and Western blots using rat or bovine antigen
were performed as previously described [14, 25]. Wells of
the ELISA plate were coated with 150 ng/50 lL antigen
for 1 hour and blocked with 1% bovine serum albumin
(BSA) for 1 hour. Horseradish peroxidase-conjugated
antirat immunoglobulins and anti-rat IgG subclasses
were purchased from Dako A/S (Glostrup, Denmark)
and Binding Site (Birmingham, UK), respectively.
Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blot were per-
formed as previously described [25]. Samples (90 lg/gel)
were applied to the gels without reduction. Proteins were
stained with Coomassie Brilliant Blue and immunos-
tained with monoclonal antibodies.
The monoclonal antibodies used for identification of
alpha chains of rat type IV collagen were epitope-
defined antibodies: H11, H22, H31, H44, and H52 [9].
Although they were raised against human a1(IV)NC1 to
a5(IV)NC1 chains, they also reacted against rat a chains.
For indirect immunofluorescence, rat, mouse, bovine,
rabbit, and human frozen kidneys were sectioned at
4 lm in a cryostat. The sections were stained with the
culture supernatant containing monoclonal antibodies
[25]. Rat cryostat sections were also stained after an acid
treatment. Rat sections were first fixed with acetone for
5 minutes, and then incubated for 20 minutes in an acid
solution (pH 1.5), containing equal amounts of 0.1 mol/L
HCl and 0.1 mol/L KCl. After they had been washed with
phosphate-buffered saline (PBS), the sections were incu-
bated with monoclonal antibodies and then with fluores-
cein isothiocyanate (FITC)-conjugated goat antibodies
against rat IgG.
Injection of female WKY/NCrj rats with
monoclonal antibody
Glomerulonephritis was induced by a single injec-
tion of antibody at various doses. The antibody was di-
luted with GIT culture medium (Wako Pure Chemical
Industries) containing 10% FBS. Using 1 mL disposable
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Table 1. Characteristics of the autoantibodies used in the present study
Indirect immunofluorescence
Enzyme-linked immunosorbent assay Western blotting
Rat Acid Rabbit Human
Clone Rat NAF Bovine NAF Rat NAF Rat treatment Mouse Bovine Intensity Intensity
name Absorbance Absorbance Pattern Intensity Intensity Intensity Intensity Intensity (pattern) (pattern)
IgG1
145 1.310 0.073 − +++ + + + +++(a34) +++(a34)
156 0.346 0.056 − +++ ++ − − − +
129 0.781 0.107 a3 + +++ ++ +++ + ++(a34) +
120 0.484 0.073 a4 + +++ + +++ − − −
159 0.861 0.051 a4 + +++ ++ +++ − + +++(a34)
114 0.818 0.061 a4 + +++ +++ +++ + +++(a34) +++(a34)
124 0.759 0.075 a4 ++ +++ ++ +++ − + −
102 0.579 0.127 a5 ++ +++ +++ − − +++(a5) −
IgG2a
a27 1.188 0.105 − +++ + − − +++(a5) −
a87 0.394 0.064 − +++ + ++ − − −
a20 0.725 0.657 − +++ ++ +++ +++ − ++
a17 0.608 0.065 a4 + +++ ++ +++ ++ ++ ++
a86 0.785 0.050 a4 + +++ +++ +++ − − +
a67 0.784 0.043 a4 + +++ +++ +++ − +++(a34) +++(a34)
a84 0.958 0.075 a4 + +++ +++ +++ − − ++
a05 1.274 0.979 a4 ++ +++ +++ − + − +++(a34)
IgG2b
b46 1.316 0.100 − +++ + + − − −
b50 1.497 1.495 − +++ ++ +++ +++ +++(a34) +++(a34)
b26 1.192 0.057 a4 + +++ + +++ − + −
b04 1.214 0.050 a4 + +++ +++ +++ − ++(a34) −
b07 1.616 0.156 a4 ++ +++ + +++ ++ + +
b35 1.525 0.058 a4 ++ +++ +++ +++ − ++(a34) −
b42 1.783 1.444 a4 ++ +++ +++ +++ +++ − −
b14 1.345 1.905 a5 + +++ ++ +++ +++ +++(a5) +++(a5)
Abbreviations are: NAF, nephritogenic antigen fraction containing NC1 domains of type IV collagen; a3, alpha 3 chain; a4, alpha 4 chain; a5, alpha 5 chain; (a34),
alpha 3 or 4 pattern; (a5), alpha 5 pattern.
plastic injectors for tuberculin, we administered 500 lL of
antibody to the abdominal cavity of rats under anesthe-
sia. The rats were without food from the previous night
in order to reduce accidental penetration of the bowel
during injection.
Urinalysis
Sixteen-hour urine (from 5:00 p.m. to 9:00 a.m.) spec-
imens were collected on days 1, 3, 5, 7, 9, and 11, after
which they were assayed for proteinuria by a modi-
fied method using 3% sulfosalicylic acid [13]. They were
also examined for hematuria with a test paper (Hema-
Combistix) (Miles-Sankyo, Tokyo, Japan). The rats were
sacrificed 12 days after the injection.
Histologic examination
Samples of renal tissue were fixed in Dubosq-Brazil
fixative, embedded in paraffin, sectioned at 3 lm, and
stained with periodic acid-methenamine-silver (PAM).
Samples of pulmonary tissue were fixed in Zamboni
fixative, embedded in paraffin, sectioned at 3 lm, and
stained with hematoxylin and eosin, and with Berlin blue
staining and nuclear fast red to confirm the presence of
hemosiderin-laden macrophages.
Direct immunofluorescence
Kidneys from rats were sliced into 3 mm sections with
a razor blade. Lungs were injected from the trachea with
a mixture of an equal amount of 22-oxacalcitriol (OCT)
compound and PBS until they became the usual swelling
size. After the injection, they were sliced into 3 mm sec-
tions. The kidneys and lungs were then embedded in OCT
compound, frozen in liquid nitrogen, and sectioned at
4 lm. After the sections had been washed with PBS, they
were incubated with a 1:50 dilution of FITC-conjugated
goat antibody against rat IgG (ICN Biomedicals, Inc.,
Irvine, CA, USA) for 30 minutes [14].
RESULTS
Monoclonal antibodies
Eight different antibodies from each of IgG1, IgG2a,
and IgG2b subclasses were used in the present study. They
were characterized by ELISA, Western blot, and indi-
rect immunofluorescence and are listed in Table 1. They
were selected in the present study because they had been
found to react with rat kidney cryostat sections with +++
intensity (Fig. 1). A comparison of the specificity of the
antibodies revealed that all of the antibodies in the same
subclass possessed different epitope specificities.
The target a chains of the antibodies were determined
by Western blot analysis. One antibody was specific for
a3(IV)NC1, 14 were specific for a4(IV)NC1, two were
specific for a5(IV)NC1, and the target a chains of the
seven remaining antibodies could not be determined by
180 Kohda et al: Nephritogenic monoclonal antibodies
Fig. 1. Staining intensity of monoclonal antibodies. Rat kidney cryo-
stat sections were stained by indirect immunofluorescence with mono-
clonal antibody b35. +++ intensity (scale bar, 100 lm). All antibodies
used in the present study showed the same pattern and intensity as this.
Western blot. However, indirect immunofluorescence us-
ing rabbit and human sections revealed two of these an-
tibodies to be against a3 or a4(IV)NC1 and one against
a5(IV)NC1 because the staining intensity of a5(IV)NC1
in Bowman’s capsule basement membrane of rabbits
and humans was much stronger than that of a3 and
a4(IV)NC1.
Relationship between antibody subclass and
severity of nephritis
The level of proteinuria and hematuria in WKY rats
injected with 300 lg/rat of monoclonal antibody on day
11, as well as the number of petechiae observed in their
lungs on day 12, are shown in Figure 2.
An unexpectedly large number of petechiae were ob-
served in the lungs of some rats. The unusually large num-
ber of petechiae seen in the lungs of one rat injected with
monoclonal antibody 156 (MA156) were not thought to
have resulted from an autoantibody response. In order to
adjust for these aberrant values, we decided to represent
the severity of pulmonary hemorrhage in terms of median
values. Similarly, we expressed the severity of proteinuria
in terms of median values and the range.
Table 2 details the severity of nephritis and extent of
pulmonary hemorrhage observed in rats injected with the
various antibodies. The range and median values of each
parameter are shown for rats injected with antibodies of
each subclass. All IgG1 antibodies induced mild protein-
uria and mild hematuria in rats, whereas all IgG2a and
IgG2b antibodies induced moderate to severe proteinuria
and severe hematuria. The range of response induced by
IgG2a was broader than that by IgG2b.
Dose-effect relationships of antibodies
of different subclasses
Monoclonal antibody 114 (MA114), monoclonal an-
tibody a84 (MAa84), and monoclonal antibody MAb35
(MAb35) were selected to represent the IgG1, IgG2a,
and IgG2b subclasses, respectively. These selected anti-
bodies were against the NC1 domain of a4(IV)NC1 and
cross-reactive with mouse GBM. Their epitopes were re-
sistant to acid treatment (Table 1). The time course of de-
velopment of proteinuria and hematuria in rats injected
with 0 to 300 lg/rat of the respective antibodies is shown
in Figure 3. Dose-effect relationships in terms of sever-
ity of nephritis and pulmonary hemorrhaging observed
are shown in Figure 4. Histologic changes are shown in
Figure 5.
MA114-induced nephritis. Hematuria was first ob-
served on day 3 in rats injected with 300 lg/rat of MA114.
Proteinuria (more than 4 mg/16 hours) and mild hema-
turia were observed from day 5 onwards in rats injected
with 100 or 300 lg/rat of MA114.
Histologic changes in the kidneys of rats injected with
300 lg/rat were mild (Fig. 5B). The changes included mild
endocapillary hypercellularity and small capsular adhe-
sion in 7% of the glomeruli.
MAa84-induced nephritis. Hematuria was first ob-
served on day 3 in rats injected with 30 lg/rat or more of
MAa84. Proteinuria and hematuria were observed from
day 3 onwards in rats injected with 10 lg/rat or more. Pro-
teinuria increased and reached a plateau on day 5. Mild
proteinuria was observed on day 5 in rats injected with
3 lg/rat of MAa84. No proteinuria or hematuria were ob-
served in rats injected with 0 (control) or 1 lg/rat of the
antibody.
The dose-effect response following injection of
MAa84, which is shown in Figure 4, demonstrates sim-
ilar levels of proteinuria following injection of 10 lg/rat
or more of MAa84, although a broad peak of proteinuria
was observed following injection of 30 to 100 lg/rat of
MAa84. A marked increase in proteinuria was observed
between doses of 3 and 10 lg/rat.
Histologic changes in the kidneys correlated well with
the degree of proteinuria observed. Both severe endocap-
illary hypercellularity and extracapillary changes, such as
capsular adhesion and crescent formation, were observed
(Fig. 5C) in 75% of the glomeruli of rats injected with
300 lg/rat by day 12.
MAb35-induced nephritis. Hematuria was first ob-
served on day 3 in rats injected with 10 lg/rat or more of
MAb35. Proteinuria and hematuria were observed from
day 3 onwards in rats injected with 3 lg/rat or more of
MAb35. Proteinuria increased and reached a plateau on
day 5. Mild proteinuria was observed on day 5 in rats in-
jected with 1 lg/rat of MAb35. No proteinuria or hema-
turia was observed in the control rats.
The dose-effect relationship of MAb35, seen in
Figure 4, shows that 3 lg/rat or more of the antibody
induced similar levels of proteinuria, although a broad
peak of proteinuria was observed at doses between 10 and
100 lg/rat. A marked increase in proteinuria was ob-
served between doses of 1 and 3 lg/rat.
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Fig. 2. Proteinuria and pulmonary hemorrhage induced by various monoclonal antibodies. The numbers above the bars represent the number of
pulmonary petechial hemorrhages observed.
Severe histologic changes were seen in the kidneys. The
glomeruli were larger than those of the control rats and
rats with MAa84-induced nephritis. By day 12, severe
endocapillary hypercellularity and severe extracapillary
changes, such as capsular adhesion and crescent forma-
tion, were observed in 98% of the glomeruli of rats in-
jected with 300 lg/rat of MAb35 (Fig. 5D).
Relationship between dose and intensity of
direct immunofluorescence
All of the monoclonal antibodies used to study the
dose-effect relationships were against a4(IV)NC1. The
a4(IV) chain was found in both the GBM and tubu-
Table 2. Proteinuria and pulmonary hemorrhage induced by
monoclonal antibodies
IgG1 IgG2a IgG2b
Number of antibodies used 8 8 8
Range of proteinuria mg/16 hours 3.2–18.1 67–173 104–182
Meidan of proteinuria mg/16 hours 6.85 128 146.5
Range of pulmonary hemorrhagea 1–7 2–115 9–455
Median of pulmonary hemorrhage 1.5 21.5 47
aNumber of petechial hemorrhages.
lar basement membrane (TBM) of rat kidneys (Fig. 1).
When antibodies against a4(IV)NC1were injected into
the abdominal cavity, they moved into the blood circula-
tion and entered the glomeruli to access GBM and TBM
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Fig. 3. Time course of urinary protein excretion in rats injected with
various doses of nephritogenic monoclonal antibodies. Closed symbols
are those with hematuria; open symbols are without hematuria. The
numbers indicate the dose of monoclonal antibody injected (lg/rat).
antigens through the fenestrae of glomerular endothelial
cells.
Direct immunofluorescence of kidneys from rats in-
jected with various doses of MAb35 are shown in
Figure 6. A faint linear deposition of antibody was seen
in the glomeruli of rats injected with 1 to 3 lg/rat of anti-
body. Intense deposition was seen in the glomeruli of rats
injected with 10 lg/rat or more. In addition, linear depo-
sition of antibody in the TBM was seen in rats injected
with 30 lg/rat or more of MAb35. Deposition of antibody
within the TBM intensified and became more diffuse as
the dose of injected antibody increased. Similar intensi-
ties of staining were observed in the GBM and TBM of
rats injected with 300 lg/rat of MAb35.
Relationship between dose and severity of
pulmonary hemorrhage
MA114 and MAa84 did not induce clear evidence of
pulmonary hemorrhage, even when doses of 300 lg/rat
were injected. On the other hand, MAb35 led to extensive
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Fig. 4. Dose-effect relationships of monoclonal antibodies of different
subclasses. Closed symbols are those with hematuria; open symbols are
without hematuria. The numbers indicate the median of number of
pulmonary petechial hemorrhages observed.
petechial hemorrhaging among the injected rats (Figs. 4
and 7). The median number of petechiae was over 600
among four rats injected with 300 lg/rat of MAb35.
Direct immunofluorescence of the lung from rats in-
jected with 300 lg of MAb35 is shown in Figure 7B.
A faint linear deposition of antibody was seen along
the alveolar basement membrane of the rats. Histolog-
ically, the lung of the rats with petechial hemorrhages
showed accumulation of intra-alveolar red blood cells
and hemosiderin-laden macrophages (Fig. 7C).
DISCUSSION
All of the IgG2a and IgG2b autoantibodies in the
present study demonstrated strong nephritogenicity in
WKY rats, whereas all of the IgG1 antibodies showed
weak nephritogenicity. This finding clearly indicates that
antibody subclass is a critical determinant of severity
of nephritis. All of the antibodies had different epitope
specificities; however, the severity of nephritis did not dif-
fer among different antibodies of the same subclass. This
indicates that the kind of target a(IV) chain of an anti-
body is not critical in determining the severity of nephritis.
In short, all IgG2a- and/or IgG2b-antibody-antigen com-
plexes on the GBM surface induced severe nephritis in
WKY rats in the present experiment.
Approximately one half of patients with anti-GBM
nephritis develop pulmonary hemorrhage, and some rats
with actively induced anti-GBM nephritis do as well [26].
It is thought that this pulmonary hemorrhage is induced
by humoral, rather than cellular, immunity, but evidence
to support this claim was lacking until now. The present
study provides concrete evidence that the pulmonary
hemorrhage in the case of anti-GBM nephritis is induced
by humoral immunity because some subclasses of mon-
oclonal antibody induced it in the present experiment.
It is interesting to note that the severity of nephritis did
Kohda et al: Nephritogenic monoclonal antibodies 183
Fig. 5. Photomicrographs of kidneys from rats injected with 300 lg of nephritogenic monoclonal antibody, taken 12 days after the injection.
Periodic acid-methenamine-silver (PAM) staining. (A) Age-matched control kidney (scale bar, 100 lm). (B) Monoclonal antibody 114 (MA114).
(C) Monoclonal antibody a84 (MAa84). (D) Monoclonal antibody b35 (MAb35).
not differ among antibodies of the same subclass but that
the severity of pulmonary hemorrhage differed markedly
with different antibodies of the same subclass. There
were exceptions to this, however, as IgG1 antibodies were
associated with mild nephritis and mild pulmonary hem-
orrhage, whereas IgG2a and IgG2b antibodies were as-
sociated with severe nephritis and severe pulmonary
hemorrhage.
Some rats with actively induced anti-GBM nephri-
tis were observed to develop pulmonary hemor-
rhage, whereas others were not [26]. Variation in the
development of pulmonary hemorrhage among rats in-
jected with the same antigen might be explained by the
type and quantity of antibodies produced by each rat (i.e.,
whether or not hemorrhagic antibodies were produced in
high titer). All rats produce nephritogenic antibody, but
some rats might produce only a very small amount of
hemorrhagic antibody.
With regard to the mechanism by which pulmonary
hemorrhage develops, it appears to be induced by de-
position of autoantibody within the alveolar basement
membrane, but not to be related to other factors, such as
kidney inflammation or protein loss from the circulation.
It is only seen when sufficient hemorrhagic autoantibody
is injected. In the present study, MAb35 was capable of
inducing pulmonary hemorrhage, but only at doses of
100 lg/rat or more. This finding might indicate that
MAb35 preferentially binds to epitopes on the GBM,
since they are more accessible than alveolar basement
membrane epitopes. After saturation of target antigens
on the GBM with antibody, excess MAb35 might bind
to target antigens on the alveolar basement membrane,
thereby inducing pulmonary hemorrhage.
Examination of the relationship between antibody
dose and effect revealed that only 1 lg/rat of IgG2b an-
tibody was required to induce nephritis. This value is far
less than expected. Examination of the pattern of depo-
sition of each autoantibody within the GBM and TBM
allowed approximation of the relative amount of autoan-
tibody produced by, or injected into, each rat.
We reported in 1989 [20] that anti-GBM nephritis can
be induced in WKY rats by injection of purified poly-
clonal antibody from the urine of rats with actively in-
duced nephritis. Under these conditions, IgG deposition
was restricted to the GBM. Judging from the antibody
staining patterns of the GBM, only about 10 lg out of
4 mg of the injected purified antibody localized to the
GBM. This indicates that only a very small amount of
nephritogenic antibody was contained in the purified
antibody.
184 Kohda et al: Nephritogenic monoclonal antibodies
Kohda et al: Nephritogenic monoclonal antibodies 185
As to the mechanism of inflammation induced after the
deposition of antibodies on the GBM, the complement
system and Fc receptors for IgG (FccR) are thought to be
involved. Rat IgG1, IgG2a and IgG2b, which is the most
effective, can bind to complement component C1q (the
initial step in the complement cascade) and induce sub-
sequent cell lysis [27]. However, neither complement C3
deposition nor infiltration of polymorphonuclear leuko-
cytes in glomeruli was found in actively and passively
induced rat models of anti-GBM nephritis. This suggests
that anti-GBM nephritis in rats is induced by a mecha-
nism independent from complement.
There are several models using mice deficient in FccRs
or in complement components. Mice have two kinds
of FccRs; the activation receptors, characterized by the
presence of a cytoplasmic immunoreceptor tyrosine-
based activation motif (ITAM) sequence of the Fc re-
ceptor c chain associated with the receptor, and the in-
hibitory receptor, characterized by the presence of an
immunoreceptor tyrosine-based inhibitory motif (ITIM)
sequence [28]. After establishing and analyzing mice de-
ficient in the Fc receptor c chain, Park et al [29] and
Wakayama et al [30] reported the importance of Fc recep-
tors but not the complement system, although they used
models of accelerated nephrotoxic serum nephritis. All
wild-type mice developed very severe glomerulonephri-
tis by administration of anti-GBM antibodies, whereas
all mice deficient in the Fc receptor c chain survived.
Suzuki et al [31] reported the effects of Fc receptors when
they used mice deficient in the Fc receptor c chain or
FccRIIB, which inhibits activation signals generated by
FccRI and FccRIII containing the ITAM. In Fc-receptor-
c-chain-deficient mice, renal injuries were dramatically
attenuated, whereas FccRIIB-deficient mice suffered ac-
celerated glomerular injuries. Their results clearly in-
dicate that induction of anti-GBM nephritis in mice is
Fc-receptor dependent and that FccRIIB plays an im-
portant role in exacerbation of anti-GBM nephritis.
Nakamura et al [32] have reported an actively induced
anti-GBM nephritis in mice deficient in FccRIIB. Defi-
cient mice immunized with the emulsion of bovine NC1
domains of type IV collagen and adjuvant showed very
severe anti-GBM nephritis with pulmonary hemorrhage,
whereas none of the wild-type mice displayed evidence
of disease. No complement C3 deposition was detected
along the GBM in the diseased mice. The mouse model
and our actively induced model in WKY rats are very
much similar in the immunization antigen, the presence
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 6. Direct immunofluorescence of cryostat sections of kidneys of rats injected with various doses of monoclonal antibody b35 (MAb35). (A)
Age-matched control kidney. (B) Faint linear staining is observed along the glomerular basement membrane (GBM). (C) Faint linear staining is
observed along the GBM, but less intense than the staining of kidneys from rats injected with 10 lg or more. (D) Intense linear staining is observed
only along the GBM not tubular basement membrane (TBM). Deposition of IgG can be seen in the crescents. (E) Intense staining is observed
along the GBM and faint staining, along the TBM. (F) Intense staining is observed along the GBM and faint to intense staining, along the TBM.
(G) Intense linear staining is observed both the GBM and the TBM. In accordance with the dose injected, monoclonal antibody is first deposited
within the GBM at the lower doses (B to D) and then also in the TBM at higher doses (E to G) (scale bar, 100 lm).
Fig. 7. Pulmonary hemorrhaging. (A) Left, control lung. Right, lung
of a rat injected with 300 lg of monoclonal antibody b35 (MAb35). (B)
Direct immunofluorescence of a cryostat section of lung of a rat injected
with 300 lg of MAb35. Weak deposition of the monoclonal antibody is
observed along the alveolar basement membrane. (C) Berlin blue stain-
ing with nuclear fast red counter staining of a paraffin-embedded lung
section of a rat injected with 300 lg of MAb35 (arrows, hemosiderin-
laden macrophages; scale bar, 100 lm).
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of anti-GBM antibody and pulmonary hemorrhage, and
no complement C3 deposition along the GBM. The sim-
ilarity suggests that FccRs play very important roles in
the pathogenesis of both actively and passively induced
anti-GBM in rats.
The present study confirms that monoclonal autoan-
tibodies are capable of inducing anti-GBM nephritis in
rats, and clarifies the subclass effect and dose effect of
various autoantibodies. In addition, we have presented
24 new monoclonal antibodies involved in anti-GBM
nephritis. These antibodies can reliably be used hereafter
to passively induced anti-GBM nephritis due to their sta-
ble specificity and everlasting nature. The rat model of
passively induced anti-GBM nephritis has tremendous
potential for examining the mechanism by which inflam-
mation is induced in human anti-GBM nephritis, as well
as for identifying potential therapeutic targets.
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